Aerie Pharmaceuticals Inc AERI
We take great care to ensure that the data presented and summarized in this overview for AERIE PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AERI
Top Purchases
Top Sells
About AERI
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Insider Transactions at AERI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2022
|
Raj Kannan Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
215,783
-100.0%
|
$3,236,745
$15.25 P/Share
|
|
Nov 21
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,585
-100.0%
|
$278,775
$15.25 P/Share
|
|
Nov 21
2022
|
Richard Croarkin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,095
-100.0%
|
$241,425
$15.25 P/Share
|
|
Nov 21
2022
|
Michael Du Toit Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,095
-100.0%
|
$241,425
$15.25 P/Share
|
|
Nov 21
2022
|
David W Gryska Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,996
-100.0%
|
$29,940
$15.25 P/Share
|
|
Nov 21
2022
|
David W Gryska Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,495
-100.0%
|
$172,425
$15.25 P/Share
|
|
Nov 21
2022
|
John La Rocca General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
53,585
-100.0%
|
$803,775
$15.25 P/Share
|
|
Nov 21
2022
|
Peter Frederick Lang Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,297
-100.0%
|
$694,455
$15.25 P/Share
|
|
Nov 21
2022
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
280,244
-100.0%
|
$4,203,660
$15.25 P/Share
|
|
Nov 21
2022
|
Peter J Mc Donnell Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,995
-100.0%
|
$119,925
$15.25 P/Share
|
|
Nov 21
2022
|
Benjamin F Mcgraw Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
41,984
-100.0%
|
$629,760
$15.25 P/Share
|
|
Nov 21
2022
|
Julie Mc Hugh Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,095
-100.0%
|
$241,425
$15.25 P/Share
|
|
Nov 01
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-0.95%
|
$2,685
$15.22 P/Share
|
|
Aug 14
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
265
-1.39%
|
$2,915
$11.57 P/Share
|
|
Aug 14
2022
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
771
-1.42%
|
$8,481
$11.57 P/Share
|
|
Jul 01
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
266
-1.38%
|
$2,128
$8.36 P/Share
|
|
Jul 01
2022
|
Jeffrey Calabrese Vice President of Finance |
BUY
Grant, award, or other acquisition
|
Direct |
11,276
+36.88%
|
-
|
|
Jun 09
2022
|
Richard Croarkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+27.95%
|
-
|
|
Jun 09
2022
|
Michael Du Toit Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+27.95%
|
-
|
|
Jun 09
2022
|
David W Gryska Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+35.2%
|
-
|